Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pan-tumor × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 140 Brain Neoplasms 64 Glioma 59 Central Nervous System Neoplasms 44 Gliosarcoma 43 Astrocytoma 35 Melanoma 28 Oligodendroglioma 27 Neuroblastoma 16 Neoplasm Metastasis 11 Medulloblastoma 10 Sarcoma, Ewing 9 Sarcoma 9 Neuroendocrine Tumors 9 Carcinoma, Non-Small-Cell Lung 9 Recurrence 8 Lung Neoplasms 8 Ependymoma 8 Neoplasms 7 Lymphoma 7 Diffuse Intrinsic Pontine Glioma 7 Breast Neoplasms 7 Rhabdomyosarcoma 6 Ovarian Neoplasms 6 Small Cell Lung Carcinoma 5 Colorectal Neoplasms 5 Carcinoma, Neuroendocrine 5 Adenoma, Islet Cell 5 Uveal Melanoma 4 Spinal Cord Neoplasms 4

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡